OITL specializes in the development and production of radiopharmaceuticals for diagnostic and therapeutic use. Radionuclides are sourced from an in-house cyclotron, commercial generators, or external suppliers, with synthesis performed manually or using automated platforms:
- Synthra RnPlus
- Trasis All-in-One
- Various Fastlab modules
Diagnostic radiopharmaceuticals
OITL develops PET and SPECT tracers labeled with a wide range of diagnostic and theranostic radionuclides. The team has broad experience in radiolabeling small molecules, peptides, and monoclonal antibodies.
Our synthesis platforms enable routine production of several tracers. A full list of tracers produced on Trasis is available here. GMP-grade [¹⁸F]FDG, [¹⁸F]NaF, [¹⁸F]PSMA, and [¹⁸F]flutemetamol are supplied by NMS.
Therapeutic radiopharmaceuticals
OITL develops radiotherapeutics by conjugating therapeutic radionuclides to targeting vectors, from small molecules to peptides and antibodies. Services include biodistribution and efficacy studies using short and long-lived radionuclides.
Custom radiotracer development
From feasibility to late-stage optimization, OITL supports custom tracer development. Manual synthesis is used in early stages, followed by automation. All processes are guided by rigorous quality control, including radio/UV-HPLC, radio-TLC, GC, and in vitro stability testing.